New psychiatric and psychological aspects of diagnosis and treatment of hepatitis C and relevance for opiate dependence

Current Opinion in Psychiatry

Volumn 18, Issue 6, 2005, Pages 678-683

  Reimer, Jens ^a   Backmund, Markus ^b   Haasen, Christian ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Klinikum Schwabing   (Germany)

Author keywords

Central nervous system; Comorbidity; Hepatitis C; Injection drug use; Psychiatric disorders

Indexed keywords

ANTIDEPRESSANT AGENT; RECOMBINANT ALPHA INTERFERON;

CLINICAL EXAMINATION; CLINICAL FEATURE; COGNITION; COMORBIDITY; CORRELATION ANALYSIS; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DRUG INDICATION; EVALUATION; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; MENTAL HEALTH CARE; NEUROTOXICITY; OPIATE ADDICTION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY;

EID: 27644451345     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000186812.01202.a5     Document Type: Review

References (57)

1. Pearlman BL. Hepatitis C infection: a clinical review. South Med J 2004; 97:365-373. This paper provides a comprehensive overview on the various aspects of HCV infection.
2. Price S, Goyette J. Role of the psychiatrist in the care of patients with hepatitis C and HIV/AIDS. Psychiatr Q 2003; 74:261-276.
3. Meyer JM. Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital. J Clin Psychiatry 2003; 64:540-545.
4. Dinwiddie SH, Shicker L, Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry 2003; 160:172-174.
5. Nakamura Y, Koh M, Miyoshi E, et al. High prevalence of the hepatitis C virus infection among the inpatients of schizophrenia and psychoactive substance abuse in Japan. Progr Neuropsychopharmacol Biol Psychiatry 2004; 28: 591-597. This important paper underlines the association of HCV infection with mental illness.
6. Garten RJ, Lai S, Zhang J, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol 2004; 33: 182-188. Given the large population in China, this paper points out dramatic epidemiologic implications.
7. Fischer B, Haydon E, Rehm J, et al. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach: the case study of Canada. J Urban Health 2004; 81:428-447. This work provides a substantiated insight into the treatment of HCV in injection drug users.
8. Mathei C, Robaeys G, van Damme, et al. Prevalence of hepatitis C in drug users in Flanders: determinants and geographic differences. Epidemiol Infect 2005; 133:127-136.
9. Butterfield MI, Bosworth HB, Stechuchak KM, et al. Racial differences in hepatitis B and hepatitis C and associated risk behaviors in veterans with severe mental illness. J Natl Med Assoc 2004; 96:43-52. This work stresses the high risk of acquisition of HCV for seriously mentally ill patients.
10. Tawk HM, Vickery K, Bisset L, et al. The significance of transfusion in the past as a risk for current hepatitis B and hepatitis C infection: a study in endoscopy patients. Transfusion 2005; 45:807-813.
11. de Ledinghen V, Trimoulet P, Cazajous G, et al. Epidemiological and phylogenetic evidence for patient-to-patient hepatitis C virus transmission during sclerotherapy of varicose veins. J Med Virol 2005; 76:279-284.
12. Pellicano R, Mladenova I, Dimitrova SM, et al. The epidemiology of hepatitis C virus infection: an update for clinicians. Minerva Gastroenterol Dietol 2004; 50:1-7. This review allows for a precise overview on epidemiologic data of HCV infection.
13. Tahan V, Karaca C, Yildirim B, et al. Sexual transmission of HCV between spouses. Am J Gastroenterol 2005; 100:821-824. This is particularly worth reading for those interested in transmission of HCV, as a sound approach to investigate the role of sexual intercourse is presented.
14. Backmund M, Reimer J, Meyer K, et al. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis 2005; 40 (Suppl 5):S330-S335. This article considers practical advice for the management of HCV in injection drug users.
15. Bacon BR. Managing hepatitis C. Am J Manag Care 2004; 10 (Suppl 2): S30-S40. This is a detailed and up-to-date approach to management of HCV infection from the hepatology perspective.
16. Siebert U, Scroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b for initial treatment of chronic hepatitis C. Gut 2003; 52:425-432.
17. Gifford SM, O'Brien ML, Smith A, et al. Australian men's experiences of living with hepatitis C virus: results from a cross-sectional survey. J Gastroenterol Hepatol 2005; 20:79-86. This study points to the numerous psychosocial problems associated with HCV infection and additionally stresses insufficient treatment access.
18. McAndrews MP, Farcnik K, Carlen P, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41:801-808. In a precisely defined sample of HCV infected subjects without significant comorbidity, neurocognitive deficits were limited stressing comorbid factors.
19. Sherman KE, Sherman SN, Chenier T, Tsevat J. Health values of patients with chronic hepatitis C infection. Arch Intern Med 2004; 164:2377-2382.
20. Hauser W, Zimmer C, Schmiedermaier P, Grandi D. Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosom Med 2004; 66:954-958. This was the first study to show that quality of life in patients with HCV is not determined by severity of liver disease, but by psychiatric and medical comorbidities and disease-related worries.
21. Dalgard O, Egeland A, Skaug K, et al. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004; 39:74-80.
22. Golub ET, Latka M, Hagan H, et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health 2004; 81:278-290.
23. Weissenberg K, Krause J, Bokemeyer M, et al. Hepatitis C virus infection affects the brain: evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41:845-851.
24. Forton DM, Thomas HC, Taylor-Robinson SD. Central nervous system involvement in hepatitis C virus infection. Metab Brain Dis 2004; 19:383-391. This is an excellent review about the effects of HCV infection on the central nervous system.
25. von Giesen HJ, Heintges T, Abbasi-Boroudjeni N, et al. Psychomotor slowing in hepatitis C and HIV infection. J Acquir Immune Defic Syndr 2004; 35:131-137.
26. Amodio P, de Toni EN, Cavalletto L, et al. Mood, cognition and EEG changes during interferon α (alpha-IFN) treatment for chronic hepatitis C. J Affect Dis 2005; 84:93-98.
27. Crone CC, Gabriel GM, Wise TN. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleveland Clinic J Med 2004; 71 (Suppl 3):S27-S32. This article provides a detailed and practical overview on the management of neuropsychiatric side effects of interferon treatment.
28. Hauser P. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFNα-induced depression. Gastroenterol Clin N Am 2004; 33:S37-S57. This is an in-depth review on etiologic and therapeutic aspects discussed in relation to interferon associated depression.
29. Kraus MR, Schäfer A, Wißmann S, et al. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther 2005; 77:90-100. The authors describe a study with a sound design pointing at the problematic, but reversible (neurocognitive) implications of interferon treatment.
30. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66:41-48. This provides determinants for development of depression under antiviral treatment for HCV.
31. Matthews SC, Paulus MP, Dimsdale JE. Contribution of functional neuroimaging to understanding neuropsychiatric side effects of interferon in hepatitis C. Psychosomatics 2004; 45:281-286. This is a concise overview on the potential of neuroimaging to elucidate neuropsychiatric effects of antiviral HCV treatment.
32. Capuron L, Raison CL, Musselman DL, et al. Association of exaggerated HPA axis response to the initial injection interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003; 160: 1342-1345.
33. Loftis JM, Wall JM, Linardatos E, et al. A quantitative assessment of depression and thyroid dysfunction secondary to interferon-α therapy in patients with hepatitis C. J Endocrinol Invest 2004; 27:16-20.
34. Maddock C, Landau S, Barry K, et al. Psychopathological symptoms during interferon-α and ribavirin treatment: effects on virological response. Mol Psychiatry 2005; 10:332-333. This paper highlights the importance of adequate treatment of interferon associated depression, also in terms of viral outcome.
35. Raison CL, Broadwell SD, Borisov AS, et al. Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C. Brain Behav Immun 2005; 19:23-27. In accordance with the work of Maddock and colleagues this paper highlights the importance of adequate treatment of interferon associated depression, also in terms of viral outcome.
36. Loftis JM, Socherman RE, Howell CD, et al. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 2004; 365:87-91.
37. Schaefer M, Schwaiger M, Garkisch, et al. Prevention of interferon-alpha associated depression psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42:793-798.
38. Kraus MR, Schäfer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepatitis 2005; 12:96-100. This study showed that a history of mental illness is no contraindication for antiviral treatment of HCV.
39. Tavakoli-Tabasi S, Rowan P, Abdul-Latif M, et al. Utility of depression score to predict candidacy for hepatitis C virus therapy in veterans: a prospective longitudinal study. Aliment Pharmacol Ther 2005; 21:235-242. This paper highlights the beneficial effects of antidepressant treatment in mentally ill people in terms of eligibility for antiviral treatment.
40. Nickel T, Sonntag A, Backmund M, Pollmacher T. Depression during therapy with interferon alpha: how long should an antidepressant treatment last? Pharmacopsychiatry 2005; 38:102-104.
41. Stein MD, Herman DS, Solomon SA, et al. Adherence to treatment of depression in active injection drug users: the Minerva study. J Substance Abuse Treatment 2004; 26:87-93.
42. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-α: recognition and management. CNS Drugs 2005; 19:105-123. An excellent in-depth overview on neuropsychiatric aspects covering relevant clinical aspects.
43. Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 2004; 161:429-435.
44. Zickmund S, Hillis SL, Barnett MJ, et al. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 2004; 39:999-1007. This work should be read by all physicians in contact with HCV infected patients, as communication problems and perceived stigmatization are addressed.
45. Hatem C, Minello A, Bresson-Hadni et al. Is the management of hepatitis C patients adequate? A population-based study. Aliment Pharmacol Ther 2005; 21:1007-1015. This large population based study in an industrialized country revealed short-comings in adequate treatment of HCV infection.
46. Rowan PJ, Tabasi S, Abdul-latif M, et al. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 2004; 38:530-534. This study with a large patient sample underscored the importance of treatable psychiatric contraindications for antiviral treatment of HCV.
47. Goldberg RW. Hepatitis and HIV screening, education, and treatment for adults with serious mental illness. Gen Hospital Psychiatry 2004; 26:167-168.
48. Stoové MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Dependence 2005; 77:81-86. This describes a study in a non-clinical sample pointing at barriers for IDUs when trying to access treatment for HCV.
49. Mauss S, Berger F, Goelz J, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-124. This study indicated the feasibility of HCV treatment whilst on methadone maintenance.
50. Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 2004; 81:719-734.
51. Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005; 40: S325-S329.
52. Sylvestre DL. Treating hepatitis C virus infection in active substance users. Clin Infect Dis 2005; 40:S321-S324. This work shows that in special settings even active drug use is no contraindication for treatment of HCV.
53. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39:1540-1543. The authors point out the low risk of HCV reinfection in injection drug users when combined with drug and psychosocial treatment.
54. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40:S336-S338. The assumption of high risk of reinfection with HCV in injection drug users is refuted by this work.
55. Sulkowski MS, Thomas DL. Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment. Clin Infect Dis 2005; 40:S263-S269.
56. NIH. Management of hepatitis C. NIH Consens Sci State Statements 2002; 19:1-46.
57. Reimer J, Schulte B, Castells X, et al. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in European Union Countries. Clin Infect Dis 2005; 40 (Suppl 5):S373-S378.